BPC 157 - Kalpa Pharmaceuticals

First brought into scientific focus in 1992, BPC-157 was developed by Croatian researcher Predrag Sikiric. The peptide was synthetically derived from a naturally occurring segment of human gastric protein, and it was investigated for regenerative purposes. Pliva Pharmaceuticals funded the early work but exited the project in 2005. Merck pursued patent acquisition shortly afterward but failed to close a deal. The compound later entered the research chemical field, with Diagen of Slovenia recognized as the chief producer.

Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.

For detailed information about BPC 157 by Kalpa Pharmaceuticals, consult with your doctor or healthcare professional.